Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
Recruiting
Phase 1
Interventional Study
HER2-positive Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 25 (estimated)
- Sponsor
- University of Alabama at Birmingham · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients must be ≥ 18 years old and ≤ 75 years old
2. HER2+ breast cancer determined on primary tumor by a local pathology laboratory and defined as IHC score 3+ and/or positive by ISH (defined by ISH ratio of ≥ 2.0 for the number of HER2 gene copies to the number of chromoso…
Contacts